Merck & Co Inc. (MRK) News Headlines

▮ More

Date

Headline

6/22/2021 7:31:27 AM Merck Says Phase III Keynote-826 Study Of Keytruda In Cervical Cancer Met Primar Endpoints

6/22/2021 2:25:04 AM AstraZeneca : EU Oks Koselugo For Children With Neurofibromatosis Type 1 & Plexiform Neurofibromas

6/22/2021 2:05:30 AM AstraZeneca: Koselugo Approved In EU For Children With NF1 And Plexiform Neurofibromas

6/17/2021 10:42:13 AM Merck Announces Deal With U.S. For Molnupiravir, Oral Antiviral Candidate For Treatment Of Mild To Moderate COVID-19

6/9/2021 7:07:06 AM Merck Inks Deal With U.S. Government To Supply 1.7 Mln Courses Of Molnupiravir - Quick Facts

6/7/2021 7:55:03 AM Merck Releases New Data From Late-stage Study Of Clear/Keynote-51

6/7/2021 6:49:03 AM Merck Presents New Investigational Data From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial

6/3/2021 10:11:58 PM AstraZeneca : Late-stage Trial Shows Lynparza Reduces Recurrence, Death In Breast Cancer Patients

6/3/2021 7:54:27 AM Merck Spins Off Organon

6/1/2021 7:06:49 AM Sanofi, Merck Announce Availability Of Six-in-one Pediatric Combination Vaccine Vaxelis In The U.S.

5/27/2021 11:24:26 PM Organon Set To Join S&P 500

5/25/2021 6:36:28 AM Xilio Therapeutics Enters Clinical Trial Collaboration With Merck To Evaluate XTX101

5/24/2021 7:09:00 AM Merck Gets Positive EU CHMP Opinion For KEYTRUDA Plus Chemotherapy For Gastrointestinal Cancers

5/20/2021 7:15:50 AM Merck Reports Positive Results From Two Trials Of V114 Phase 3 Pediatric Clinical Program

5/13/2021 7:41:16 AM Merck Says Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint In Patients With Breast Cancer

5/6/2021 9:50:15 AM Fusion, Merck To Evaluate Fusion's Targeted Alpha Therapy In Combination With Merck's KEYTRUDA

5/6/2021 9:23:50 AM Fusion Collaborates With Merck To Evaluate Fusion' TAT In Combination With Merck' KEYTRUDA In Patients With Solid Tumors

5/6/2021 6:50:20 AM Merck To Present Data Spanning More Than 20 Cancer Types From Its Oncology Research Program At ASCO

5/3/2021 8:05:53 AM Merck: Spinoff Organon Expected To Drive Sustainable Growth

5/3/2021 6:48:58 AM Merck: Organon's Standalone Co. To Deliver Low To Mid-single Digit Revenue Growth Off 2021 Base